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Asparaginase-associated pancreatitis is a life-threatening toxicityto childhood acute lymphoblastic leukemia treatment. To eluci-date genetic predisposition and asparaginase-associated pancre-
atitis pathogenesis, ten trial groups contributed remission samples
from patients aged 1.0−17.9 years treated for acute lymphoblastic
leukemia between 2000 and 2016. Cases (n=244) were defined by the
presence of at least two of the following criteria: (i) abdominal pain;
(ii) levels of pancreatic enzymes ≥3 x upper normal limit; and (iii)
imaging compatible with pancreatitis. Controls (n=1320) completed
intended asparaginase therapy, with 78% receiving ≥8 injections of
pegylated-asparaginase, without developing asparaginase-associated
pancreatitis. rs62228256 on 20q13.2 showed the strongest association
with the development of asparaginase-associated pancreatitis (odds
ratio=3.75; P=5.2x10-8). Moreover, rs13228878 (OR=0.61; P=7.1x10-6)
and rs10273639 (OR=0.62; P=1.1x10-5) on 7q34 showed significant
association with the risk of asparaginase-associated pancreatitis. A
Dana Farber Cancer Institute ALL Consortium cohort consisting of
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Introduction
Intensification of chemotherapy for childhood acute
lymphoblastic leukemia (ALL) has generated 5-year sur-
vival rates greater than 90%, but has been associated with
an increase in therapy-related toxicity.1 Asparaginase is a
key drug in the treatment of childhood ALL and there is
growing interest in its use as an anti-metastatic agent in
breast cancer.2 Asparaginase depletes the body of the non-
essential amino acid asparagine through deamidation of
asparagine into aspartic acid and ammonia,3 and targets
protein synthesis in malignant lymphoblasts by impairing
the ability to synthesize asparagine.4,5 Pancreatitis associ-
ated with asparaginase therapy (AAP) is a frequent toxici-
ty affecting 4−10% of children treated on contemporary
ALL protocols, and is associated with severe complica-
tions.6–9 In addition, re-exposure to asparaginase after AAP
is associated with a high risk (~50%) of a second episode
of AAP, and thus AAP often entails truncation of asparag-
inase therapy, thereby decreasing the patients’ chance of
survival.4,5,9 The mechanism(s) by which asparaginase
causes pancreatitis are elusive, thus hampering attempts
to identify patients with an altered risk of AAP.10 The
Ponte di Legno toxicity working group, therefore, initiated
a study with three main purposes: (i) to define diagnostic
consensus criteria for AAP;11 (ii) to describe the phenotype
of AAP in patients across multiple ALL trial groups;9 and
(iii) to explore genotype-phenotype associations, using a
genome-wide approach, to identify patients with altered
risk of AAP.9,11 Genome-wide association (GWA) studies
are agnostic by design, reporting phenotype-genotype
associations without prior hypotheses and often including
speculative mechanisms. Replication of GWA study
results are thus a requisite for credibility Accordingly, this
study presents results from the largest AAP GWA study so
far, with a strong focus on investigating previously validat-
ed variants associated with non-asparaginase-induced
pancreatitis and replicating top results in similar childhood
ALL cohorts. 
Methods
Study design and participants
Ten international childhood ALL trial groups (Online
Supplementary Table S1) contributed to the discovery cohort. Post-
remission DNA was collected from June 2015 to January 2017,
three groups collected DNA on AAP cases only while seven
groups did so on both cases and controls (Online Supplementary
Figure S1). The database containing phenotype data was approved
by the regional ethical review board of The Capital Region of
Denmark (H-2-2010-022), the Danish Data Protection Authorities
(j.nr.: 2012-58-0004), and by relevant regulatory authorities in all
participating countries. Genotype data were stored at the
Technical University of Denmark’s server Computerome.12
Children (aged 1.0–17.9 years) with newly diagnosed ALL
between January 2000 and January 2016 were eligible, irrespective
of ethnicity. Pancreatitis was defined as asparaginase-associated if
diagnosed within 50 days of the last injection of native E. coli
asparaginase or polyethylene glycolated E. coli asparaginase (PEG-
asparaginase) and cases fulfilled the Ponte di Legno toxicity work-
ing group consensus definition for AAP: i.e., at least two of (i)
amylase, pancreatic amylase, or pancreatic lipase ≥3 x upper nor-
mal limit; (ii) abdominal pain; and (iii) imaging compatible with
imaging compatible with pancreatitis. All controls received the
planned amount of asparaginase therapy in their respective proto-
cols, with more than 78% (1024/1320) receiving at least eight
injections of PEG-asparaginase without developing AAP. A subset
of 62 AAP cases was previously included in a Nordic Society of
Pediatric Hematology and Oncology (NOPHO) GWA study.13
These samples were genotyped on identical genotyping arrays as
the remaining cohort, and raw genotyping data on these patients
were pooled with those of the remaining cohort prior to quality
control, and association analyses were done in one cohort. 
Genotyping
Post-remission DNA was genotyped by Aros Applied
Biotechnology A/S (Aarhus, Denmark) on Illumina
Omni2.5exome-8 BeadChip arrays using the human genome
assembly (GRCh37) for reference. Quality control was performed
using the PLINK tool,14 and single nucleotide polymorphisms
(SNPs) were annotated in Ensembl Variant Effect Predictor
GCRCh37.15 Alleles given are refSNP alleles according to dbSNP
(not necessarily the alleles supplied by the Illumina map).16 
Quality control
Quality control was performed according to previously pub-
lished criteria17 (Online Supplementary Figures S2-4), excluding indi-
viduals with: (i) a discordance in number of X chromosomes
between geno- and phenotypes; (ii) missing data on >3% of SNPs;
(iii) excess heterozygosity between autosomal SNPs; and (iv) high
relatedness between samples. SNPs were excluded based on: (i)
missing data on >2% of individuals (call rate); (ii) Hardy-Weinberg
equilibrium; (iii) minor allele frequency <0.01; (iv) difference in call
rate between cases and controls (Fisher exact test P<1.10-5); and (v)
duplicated genomic position. 
patients treated on protocols between 1987 and 2004 (controls=285, cases=33), and the Children’s
Oncology Group AALL0232 cohort (controls=2653, cases=76) were available as replication cohorts
for the 20q13.2 and 7q34 variants, respectively. While rs62228256 was not validated as a risk factor
(P=0.77), both rs13228878 (P=0.03) and rs10273639 (P=0.04) were. rs13228878 and rs10273639 are in
high linkage disequilibrium (r2=0.94) and associated with elevated expression of the PRSS1 gene,
which encodes for trypsinogen, and are known risk variants for alcohol-associated and sporadic pan-
creatitis in adults. Intra-pancreatic trypsinogen cleavage to proteolytic trypsin induces autodigestion
and pancreatitis. In conclusion, this study finds a shared genetic predisposition between asparagi-
nase-associated pancreatitis and non-asparaginase-associated pancreatitis, and targeting the trypsino-
gen activation pathway may enable identification of effective interventions for asparaginase-associ-
ated pancreatitis.
Replication
Three top SNPs were tested for validation in two separate
cohorts. The Children’s Oncology Group AALL0232 ALL cohort
included previously genotyped data on PRSS1-2 variants (but not
on the NFATC2 variant). The NFATC2 variant was genotyped de
novo in a cohort of patients from the Dana Farber Cancer Institute
(DFCI) ALL Consortium protocols 87−01, 91−01, 95−01 and
00−01 (1987-2004). The AALL0232 ALL cohort included 76 cases
diagnosed using National Cancer Institute’s Common
Terminology Criteria for Adverse Events (CTCAE criteria) (Online
Supplement pages 6−9) and 2577 controls.8 The cohort is described
in detail in the appendix.8 The AALL0232 cohort was genotyped
on the Affymetrix Genome-Wide Human SNP 6.0 Array, and
imputed genotypes were generated using 1000 Genomes as the
reference population as reported (ref: PMID 26265699). Time-
dependent analysis (Cox proportional hazards regression) was
performed adjusting for age and ancestry. The cohort of patients
treated on the DFCI ALL Consortium protocols 87−01, 91−01,
95−01 and 00−01 received 20−30 weeks of post-induction
asparaginase therapy (Online Supplement pages 9-11). Thirty-three
cases diagnosed according to the CTCAE criteria and 285 controls
were included in this cohort, and genotyped by allele-specific
oligonucleotide hybridization as described elsewhere.18,19 The
Pearson correlation coefficient was used to investigate associa-
tions between genotype and AAP. 
Statistical analysis
Association analysis was done in PLINK using logistic regres-
sion, assuming an additive genetic model, and adjusting for genet-
ic ancestry and age. Genetic ancestry was determined by cluster-
ing analysis, and non-CEU ancestry was defined as individuals
>16 standard deviations away from the HapMap-defined CEU
(Northern and Western European) centroid mean. Using this
model, multidimensional scaling plots showed an equal distribu-
tion of cases and controls according to ancestry (Online
Supplementary Figure S3) and QQ plots showed no sign of popula-
tion substructure (λ = 1.02, Online Supplementary Figure S4).
Statistical analysis of phenotype and genotype associations was
performed in the statistical program R version 3.3.3.20 Linear and
logistic regression analyses were used to identify associations
between genotypes and continuous or categorical clinical variables
adjusting for age and ancestry. Genotype was treated as a numer-
ical value (0, 1 or 2 minor alleles) for additive effect. The Kaplan-
Meier method was used to estimate probability of event-free sur-
vival according to genotypes, and differences were compared with
the two-sided log-rank test. No prior sample size calculations
were applied for pre-study power calculations. Two-sided P-val-
ues below 0.05 were regarded as statistically significant. SNPs
were annotated to genes 10 kb up- or downstream from transcrip-
tion start- and end-sites, respectively, and all SNPs with a P-value
below 5 x 10-5 were manually inspected for associations with
genes and pathways previously related to pancreatitis.
Investigated SNPs were explored using dbSNP16 and Ensembl,15
linkage disequilibrium (LD) between SNPs by the National Cancer
Institute LDassoc tool,21 tissue expression (expressive quantitative
trait loci) by GTeX,22 regulatory effect by RegulomeDB,23 and
regional association plots were produced by the LocusZoom
tool.24 Genes and SNPs previously associated with pancreatitis
were investigated by searching PubMed for reports published in
English within the last 10 years, using the search terms “pancreati-
tis” AND “genome” OR “genetic” OR “genotype” in the title. Gene
functions were defined by Genecards25 (www.genecards.org).
Results
After quality control filtering, 244 cases, 1320 controls
and 1401908 SNPs were eligible for association analysis.
Two hundred and five of the 244 (84%) cases and
1185/1320 (90%) of controls were of European (CEU)
ancestry (Online Supplementary Figure S4). The median age
(interquartile range, IQR) of the cases was 8.1 years (IQR,
4.3 to 13.1) while that of the controls was 5.0 years (IQR,
3.0 to 9.0). Fifty-five percent of both cases (133/244) and
controls (724/1320) were male.
Figure 1 shows the significance of SNPs associated with
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Figure 1.Manhattan plot. Manhattan plot showing single nucleotide polymorphisms (SNPs) associated with asparaginase-associated pancreatitis in 244 cases and
1320 controls. The x axis represents genomic location, and the y axis represents the P value for the SNP associations calculated using logistic regression adjusting
for age and ancestry. Genes previously associated with pancreatitis are represented in color. SNPs are annotated to genes based on genomic location (10 kb
upstream and downstream of the transcription start site and transcription terminator, respectively. The human assembly GRCh37 was used for reference.
AAP. The variant rs62228256 [reference allele=C, minor
allele=T (C>T)] on 20q13.2 showed the strongest associa-
tion with AAP [odds ratio (OR), 3.75; 95% confidence
interval (95% CI): 2.33 to 6.04; P=5.2 x 10-8). rs62228256 is
located 274 kilobase pairs upstream of Nuclear factor of
activated T cells (NFATC2) and has been documented to
be an expressive quantitative trait locus for this gene in
pancreatic tissue (Online Supplementary Figure S5). 
The 30 SNPs most associated with AAP, with P-values of
5 x 10-5 or lower, included rs13228878 (A>G; OR, 0.61;
95% CI: 0.5 to 0.76; P=7.1 x 10-6) and rs10273639 (C>T;
OR, 0.62; 95% CI: 0.5 to 0.77; P=1.1 x 10-5) (Table 1). These
SNPs reside on the same haplotype and are in high LD
(CEU population LD; r2=0.94) in the PRSS1-PRSS2 locus
on chromosome 7 (Figure 2). PRSS1 and PRSS2 encode for
the proteases cationic and anionic trypsinogen, respective-
ly. Both minor alleles rs13228878_G and rs10273639_T
reduce the risk of AAP. When performing association
analysis in the CEU population of 205 AAP cases and 1185
controls, rs62228256 (OR, 3.75; 95% CI: 2.27 to 6.2;
P=2.47 x 10-7), rs13228878 (OR, 0.60; 95% CI: 0.48 to 0.76;
P=2.1 x 10-5) and rs10273639 (OR, 0.62; 95% CI: 0.49 to
0.78; P=3.8 x 10-5) (Online Supplementary Figures S6-8 and
Online Supplementary Table S2) remained strongly associat-
ed with AAP. Further investigation of previously validated
SNPs within genes known to regulate trypsin activation26
(Online Supplementary Table S3) showed that AAP was
associated with rs17107315 in pancreatic secretory trypsin
inhibitor (SPINK1; OR, 2.87; 95% CI: 1.36 to 5.8; P=4 x
10-3), rs10436957 in chymotrypsin C (CTRC; OR, 0.69;
95% CI: 0.53 to 0.89; P=5 x 10-3) and rs4409525 in Claudin-
2 (CLDN2; OR, 1.41; 95% CI: 1.08 to 1.83; P=0.01) with all
minor alleles altering AAP risk in the direction and with
effects very similar to those previously reported. 
In a logistic regression model, testing whether the effect
of the most associated PRSS1-PRSS2 variant (rs13228878)
was modified by rs17107315 (SPINK1), rs10436957
(CTRC) and rs4409525 (CLDN2), no significant interac-
tions were identified (P=0.48, P=0.95 and P=0.93, respec-
tively). 
Pancreatitis in childhood ALL
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Table 1. Top 30 single nucleotide polymorphisms.
          SNP                Chr        Position       Major>minor      MAF          MAF          OR (95% CI)          P-value                                Gene
                                                                         allele            cases      controls                                                                    (distance from gene)
      rs62228256               20           50454447                 C>T                 0.07              0.02           3.75 (2.33-6.04)         5.18x10-8
      rs7270119                20           50436587                 A>G                 0.07              0.02            3.64 (2.28-5.8)          5.52x10-8
      rs16996276               20           50455925                 A>C                 0.07              0.02           3.64 (2.27-5.85)         8.64x10-8                                            
     rs62228230               20           50445082                 G>A                 0.07              0.02           3.54 (2.23-5.63)         9.19x10-8                                            
        rs934350                 13          103589776                A>G                 0.32              0.22            1.84 (1.47-2.3)          1.16x10-7                                            
       rs170623                  9           101984936               C>G                 0.38              0.28           1.78 (1.42-2.22)         3.93x10-7               ALG2 (+0.69 kb) & SEC61B (0)
      rs75245362               14           95990645                 C>T                 0.11              0.05           2.46 (1.73-3.51)         6.33x10-7      SCARNA13 (-9.05 kb) & SNHG10 (-8.6 kb)
    rs368819120              12           71747240                 G>-                 0.48              0.37           1.67 (1.35-2.06)         2.04x10-6                                            
       rs4769201                13           22698015                 A>G                 0.04              0.01           4.66 (2.45-8.86)         2.67x10-6                                            
      rs7851954                 9             6796167                  C>T                 0.28              0.40           0.59 (0.47-0.74)         3.02x10-6                                 KDM4C (0)
      rs61734424               19           50747533                 T>C                 0.08              0.04             2.75 (1.8-4.2)           3.04x10-6                                  MYH14 (0)
      rs9912225                17            4680732                  A>G                 0.10              0.05            2.42 (1.67-3.5)          3.10x10-6                TM4SF5 (0) & VMO1 (-7.8 kb)
       rs7155612                14           95976755                 T>G                 0.12              0.06            2.24 (1.6-3.15)          3.15x10-6                                            
      rs2167730                 8            78103417                 T>C                 0.24              0.34           0.57 (0.45-0.73)        3.69 x10-6                                            
      rs80170196               19           50747159                 C>T                 0.08              0.04           2.73 (1.78-4.18)         3.77x10-6                                  MYH14 (0)
     rs62228228               20           50443845                 G>A                 0.06              0.02           3.15 (1.94-5.13)         3.80x10-6                                            
       rs5010616                12           71748290                 C>T                 0.48              0.37              1.63 (1.32-2)           4.76x10-6                                            
     rs12494164                3           164967758                A>C                 0.23              0.14           1.77 (1.39-2.27)         4.83x10-6                                            
      rs16848986                3           164979570                T>C                 0.22              0.14           1.77 (1.38-2.26)         5.19x10-6                                            
     rs34375180               12           71779640                 G>A                 0.49              0.38           1.61 (1.31-1.98)         5.53x10-6                                            
       rs7139808                13           22693228                 T>C                 0.04              0.01           4.59 (2.38-8.87)         5.59x10-6                                            
     rs12582343               12           71766297                 A>G                 0.48              0.38           1.62 (1.31-1.99)         5.90x10-6                                            
      rs13228878                7           142473466                A>G                 0.35              0.44            0.61 (0.5-0.76)          7.06x10-6        PRSS2 (-6.44 kb) & PRSS3P2 (-5.29 kb)
      rs6477109                 9             6794938                  C>T                 0.29              0.40           0.61 (0.49-0.75)         7.64x10-6                                 KDM4C (0)
      rs74109922               13          103582300                A>G                 0.12              0.06           2.13 (1.52-2.97)         1.03x10-5                                            
      rs1505495                 4           172973580                A>C                 0.10              0.17           0.48 (0.34-0.66)         1.06x10-5                                GALNTL6 (0)
       rs1791520                18           22118315                 T>C                 0.32              0.23           1.65 (1.32-2.07)         1.12x10-5                                            
     rs10273639                7           142456928                C>T                 0.35              0.44            0.62 (0.5-0.77)          1.13x10-5                              PRSS1 (-0.4 kb)
       rs4655107                 1            23094454                 G>A                 0.13              0.24            0.53 (0.39-0.7)          1.16x10-5                                  EPHB2 (0)
     rs55634345                4            19846813                 G>A                 0.46              0.34           1.58 (1.29-1.94)         1.19x10-5                                            
Top 30 SNPs most associated with AAP in 244 cases and 1320 controls. The model used here includes covariates for age and genetic ancestry.  SNPs were annotated to genes if
≤10 kb upstream (-) or downstream (+) of the transcription start site or transcription terminator, respectively. SNP: single nucleotide polymorphism; Chr,: chromosome; MAF: minor
allele frequency; OR: odds ratio; CI: confidence interval.
Validation of results
In validating our top SNP in the NFATC2 locus
(rs62228256) and top SNPs in the PRSS1-PRSS2 locus
(rs13228878 and rs10273639) we used two cohorts of chil-
dren with ALL: one treated according to the DFCI ALL
Consortium 87−01, 91−01, 95−01 and 00−01 protocols,27,28
and the other according to Children’s Oncology Group
AALL0232 protocol8 (Online Supplement pages 6−12).
Whereas the association between AAP and rs6228256
genotype was not replicated in the DFCI ALL Consortium
cohort (P=0.77, Online Supplement page 10), both
rs13228878 (hazard ratio, 0.68; 95% CI: 0.48 to 0.96;
P=0.03) and rs10273639 (hazard ratio, 0.69; 95% CI: 0.49
to 0.98; P=0.04) were significantly associated with the risk
of developing pancreatitis in the AALL0232 cohort (Online
Supplement page 8).
Two previous studies have investigated SNPs associated
with pancreatitis in children with ALL. Using different
diagnostic criteria for pancreatitis and including controls
with less than 5 weeks of asparaginase therapy, Liu et al.
associated the rare variant (general population minor allele
frequency=0.009%) rs199695765 in carboxypeptidase A2
encoding CPA2 (hazard ratio, 587; 95% CI: 66.8 to 5166;
P=9 x 10-9) with AAP.8 We did not directly genotype this
SNP, and none of the genotyped SNPs in the CPA2 region
was in LD with rs199695765. Of 32 SNPs 10 kb up- and
down-stream of CPA2, rs66839817 (T>C, OR, 1.28; 95%
CI: 1.03 to 1.57; P=0.02) showed the strongest association. 
In a NOPHO GWA study we previously found the
ULK2 variant rs281366 (P=5.8 x 10-7) and RGS6 variant
rs17179470 (P=1.3 x 10-6) to be most associated with
AAP.13 Excluding cases and controls from the NOPHO
study, we failed to validate these results in 184 cases and
712 controls. Both rs281366 and rs17179470 were directly
genotyped in this cohort with non-significant P-values
(P=0.84 and P=0.32, respectively).
Genotype-phenotype associations 
Table 2 shows associations between PRSS1-PRSS2
genotype and amount of PEG-asparaginase given prior to
AAP, days from PEG-asparaginase injection to AAP, com-
plications of pancreatitis, and risk of a second episode of
AAP after re-exposure to asparaginase. The risk allele was
not associated with number of PEG-asparaginase injec-
tions prior to AAP or time from injection of PEG-asparag-
inase to diagnosis of AAP. Furthermore, the risk of devel-
oping acute complications was not found to be associated
with PRSS1-PRSS2 genotype (Table 2). In the Nordic sub-
set of cases (n=92) and controls (n=1024) we found no
association between PRSS1-PRSS2 genotype and 5-year
event-free survival (Online Supplementary Figure S9; P=0.4).
Out of 46 children who were re-exposed to asparaginase,
17 (37%) developed a second episode of AAP; although
not in a statistically significant manner, the PRSS1-PRSS2
minor allele indicated the same protective effect as in the
risk of initial AAP (OR, 0.49; 95% CI: 0.15 to 1.41;
P=0.20). 
Discussion
This study is the first to find and validate variants in the
PRSS1-PRSS2 locus associated with the risk of AAP in
children with ALL. In doing so, we found that activation
of trypsin within pancreatic acinar cells is a key initiating
event in the pathogenesis of pancreatitis, regardless of the
exposure i.e. alcohol, hyperlipidemia, or asparaginase.
The role of trypsin activation in the pathogenesis of pan-
creatitis had long been suspected, but an underlying genet-
ic susceptibility was not documented until 1996 when
Whitcomb et al. documented mutations in the PRSS1 gene
causing hereditary pancreatitis,29 and later associated a
common genetic variant in the PRSS1-PRSS2 locus
(rs10273639) with the risk of alcohol-related and sporadic
pancreatitis.30 This association was recently validated in
larger European and Asian cohorts, and the haplotype has
been studied in detail.31–33 rs10273639 is located 408 base
pairs upstream of the translation initiation codon of
cationic trypsinogen. A recent functional study document-
ed that the proximal rs4726576 (C>A) variant (204 kb
upstream of the translation initiation codon) drives the
association.34 The rs4726576 and rs10273639 variants are
in high LD (r2 >99%) in European and Asian populations
but have a r2 = 0.8 in the African meta-population, and
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Figure 2. Regional  associa-
tion plot of the PRSS1-2 locus
on chromosome 7. Regional
asssociation plot showing sin-
gle nucleotide polymorphisms
(SNPs) associated with
asparaginase-associated pan-
creatitis in 244 cases and
1320 controls. The x axis rep-
resents genomic location, and
the y axis represents the P val-
ues for the SNP associations
calculated using logistic
regression adjusting for age
and ancestry. rs13228878
(P=7.1 x 10-6) is represented in
purple and rs10273639
(P=1.1 x 10-5) in red. The color
of the dots reflects linkage
disequilibrium (LD) of the
genotyped SNPs. LD is based
on 1000 genomes European
samples, November 2014.
The human assembly GRCh37
was used for reference.
pinpointing the association driving the signal is thus of
importance in the latter population. Sequencing the
PRSS1-PRSS2 risk allele has not revealed disease-associat-
ed coding variants accounting for the association with
pancreatitis in GWA studies; however, the risk allele
(rs4726576; rs10273639) is an expressive quantitative trait
locus for PRSS1 shown to elevate gene expression.30,34
The activation of trypsinogen is mediated by cleavage
of the N-terminus extension of cationic trypsinogen (a cal-
cium binding site) to active trypsin. Higher levels of calci-
um have been shown to lead to trypsin activation, and
with higher expression of trypsin as seen in patients with
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Table 2. Baseline characteristics, pancreatic enzyme levels and complications of pancreatitis in children according to the PRSS1-2 (rs13228878) geno-
type.
                                                     Homozygote for rs13228878_A        Heterozygote for rs13228878_A            Homozygote for rs13228878_G            P
                                                                       risk allele                                            risk allele                                           non- risk allele
                                                                         n=104                                                 n=109                                                      n=30
Age (years), median                                                      7.75                                                                 9.21                                                                      6.22                                       0.27
(median; IQR)                                                           (4–12.06)                                                   (4.46–13.43)                                                        (4.9–12.1)
Sex, % males                                                                   53%                                                                55%                                                                      57%                                       0.92
n. males/total))                                                          (55/104)                                                        (60/109)                                                               (17/30)
Total amylase at diagnosis                                           397                                                                  382                                                                       222                                        0.33
of AAP (U/L) median                                        (263–673; n= 43)                                        (206–671; n=51)                                              (151–617; n=14)
(IQR; n. available data)                                                                                                                                                                                                                                                       
Lipase at diagnosis of AAP (U/L)                              1255                                                                1096                                                                      867                                        0.24
median (IQR; n. available data)                    (758–2140; n=39)                                       (415–1754; n=48)                                            (193–2862; n=11)                              
Days from last PEG- asparaginase                             10.5                                                                 10.5                                                                        11                                         0.96
exposure to AAP, median                                    (6–16; n=70)                                               (6–14; n=82)                                                  (8–13.25; n=16)
(IQR; n. available data)                                                     
Number of PEG-asparaginase                                       4                                                                      3                                                                          3.5                                        0.34
administrations prior to AAP, median                (2–7; n=74)                                                 (2–6; n=85)                                                 (1.25–6.75; n=18)
(IQR; n. available data)                                                    
Assisted mechanical ventilation, %                            5%                                                                   7%                                                                        0%                                        0.38
(yes (n.)/available data (n.))                                    (5/93)                                                           (7/101)                                                                  0/26                                           
Acute insulin therapy, %                                               21%                                                                23%                                                                      18%                                       0.88
(yes (n.)/available data (n.))                                   (17/80)                                                          (20/87)                                                                 (4/22)                                         
Pseudocysts, %                                                               25%                                                                31%                                                                       8%                                        0.07
(yes (n.)/available data (n.))                                   (22/89)                                                         (31/100)                                                                (2/24)
Death, %                                                                            3%                                                                   1%                                                                        0%                                        0.38
(yes (n.)/available data (n.))                                    (3/93)                                                           (1/101)                                                                 (0/27)
Baseline characteristics, pancreatic enzyme levels and complications of  pancreatitis according to rs13228878 genotype. Differences among groups were analyzed with the Kruskal-Wallis
rank sum test (continuous variables) and chi-square test (categorical variables).
Figure 3. Schematic drawing illustrating the effects of asparaginase on pancreatic acinar cells. Schematic drawing illustrating the likely effect of asparaginase (red
triangle) on the protease-activated receptor 2 (PAR2) receptor, and how this leads to increased calcium (Ca++) efflux from the endoplasmic reticulum. This in turn
leads to opening of Ca++ release activated (CRAC) channels, further increasing intracellular calcium levels, reducing ATP levels and allowing activation of inactive
trypsinogen to active trypsin. The drawing is heavily influenced by diagrams by Peng et al. (Phil Trans Royal Soc, 2015) and Whitcomb et al. (Nature Gen, 2012).
the (rs4726576; rs10273639) risk allele, these patients are
at higher risk of trypsin activation and pancreatitis.26 In a
study investigating the effect of asparaginase on pancreat-
ic acinar cells, asparaginase evoked intracellular calcium
release from the endoplasmic reticulum mediated by the
protease-activated receptor 2 (Figure 3). This elevation in
calcium levels in turn activated calcium release activated
calcium (CRAC) channels further increasing intracellular
calcium levels, leading to decreased ATP levels, trypsin
activation and necrosis.35 The pancreatitis-causing mecha-
nism seems to be independent of the anti-neoplastic effect
of asparaginase, and drugs inhibiting CRAC channels
could thus be used to prevent AAP during asparaginase
therapy, not least in patients who are re-exposed to
asparaginase after having had AAP, since these patients
have a ~50% risk or developing a second episode of
AAP.9,13
The NFATC2 associated variant rs62228256 was most
significantly associated with AAP. However, with no asso-
ciation found in the replication study and no association
with pancreatitis found in adult studies on non-asparagi-
nase associated pancreatitis,26 the association between
NFATC2 and AAP seems to have low credibility. We were
not able to associate the PRSS1-PRSS2 genotype to risk of
AAP-related complications, indicating that this allele only
alters the risk of AAP, while the complications are a result
of other factors. The validation of our PRSS1-PRSS2 top
SNPs in the AALL0232 cohort strengthens the credibility
of this result. The association was of similar effect size,
but of borderline statistical significance, which may reflect
three key issues: (i) diagnostic criteria differ between the
cohorts, and cases are not completely comparable; (ii) pan-
creatitis is strongly associated with asparaginase exposure,
and it was a prerequisite that included controls received a
significant amount of asparaginase to reduce the risk of
false negative controls; and (iii) the validation cohort was
relatively small.36,37
Our results need to be judged in the light of their limita-
tions. The association analyses were strongly influenced
by individuals of CEU ethnicity, and we cannot determine
the effects in non-CEU populations. Moreover, our results
for the PRSS1-PRSS2 locus did not reach genome-wide
significance with a P-value <5 x 10-8. This highlights a
challenge when doing GWA studies in cohorts of limited
size, as will often be the case in childhood ALL, and
requires strategies for validation in independent and simi-
lar cohorts. In this present study, we attempted to limit
the problem of limited sample size by improving the qual-
ity of phenotyping, collecting individual clinical data on
AAP cases and including controls with documented com-
pletion of extensive asparaginase therapy. 
In conclusion, we found that children who develop AAP
possess identical genetic risk variants as adults with non-
asparaginase-associated pancreatitis. This may allow
future preventive measures for reduction of AAP.     
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